Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SRZN
STRONG SELLSurrozen, Inc. · Healthcare · United States · $229M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Surrozen, Inc. is a biotechnology company focused on developing regenerative medicines by modulating the Wnt signaling pathway to repair and regenerate damaged tissues and organs. The company's proprietary technologies aim to precisely activate Wnt signaling in a tissue-specific manner, offering a novel approach to treating various diseases with high unmet medical needs, including liver disease and inflammatory bowel disease. Its innovative platform for Wnt pathway modulation provides a strong, specialized competitive moat in the regenerative medicine space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.5M | 0 | 10.7M | 3.5M | -34.7% | 7.5M | 5.9M | 3.5M | -0.0% |
| EPS | -2.70 | -3.79 | -6.09 | -32.37 | — | -36.87 | — | — | — |
| Shares | 11.6M | 11.6M | 11.6M | 9.8M | -15.8% | 11.6M | — | — | — |
| Debt | 5.6M | 3.4M | 8.5M | 6.6M | 5.8% | 6.8M | — | — | — |
| Equity | 76.0M | 37.9M | -21.4M | -187.8M | -50.1% | — | — | — | — |
| Op CF | -44.1M | -40.4M | -17.6M | -30.2M | — | -33.5M | — | — | — |
| Inv CF | 38.3M | 51.7M | -26.0K | -0.1M | — | — | — | — | — |
| Fin CF | -2.6M | 0.3M | 16.2M | 85.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SRZN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SRZN | Surrozen, Inc.(you) | $229M | 15 | STRONG SELL |
| FULC | Fulcrum Therapeutics, Inc. | $248M | 15 | STRONG SELL |
| NAUT | Nautilus Biotechnology, Inc. | $215M | 14 | STRONG SELL |
| RNAC | Cartesian Therapeutics, Inc. | $232M | 12 | STRONG SELL |
| TARA | Protara Therapeutics, Inc. | $226M | 12 | STRONG SELL |
| RNA | Atrium Therapeutics, Inc. | $197M | 16 | STRONG SELL |
| VYGR | Voyager Therapeutics, Inc. | $187M | 15 | STRONG SELL |
| IRD | Opus Genetics, Inc. | $254M | 13 | STRONG SELL |
| NERV | Minerva Neurosciences, Inc. | $188M | 16 | STRONG SELL |
| CHRS | Coherus Oncology, Inc. | $217M | 20 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%